Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix
High-grade neuroendocrine cervical cancers (NETc) are exceedingly rare, highly aggressive tumors. We analyzed 64 NETc tumor samples by whole-exome sequencing (WES). Human papillomavirus DNA was detected in 65.6% (42/64) of the tumors. Recurrent mutations were identified in PIK3CA, KMT2D/MLL2, K-RAS, ARID1A, NOTCH2, and RPL10. The top mutated genes included RB1, ARID1A, PTEN, KMT2D/MLL2, and WDFY3, a gene not yet implicated in NETc. Somatic CNV analysis identified two copy number gains (3q27.1 and 19q13.12) and five copy number losses (1p36.21/5q31.3/6p22.2/9q21.11/11p15.5). Also, gene fusions affecting the ACLY-CRHR1 and PVT1-MYC genes were identified in one of the eight samples subjected to RNA sequencing. To resolve evolutionary history, multiregion WES in NETc admixed with adenocarcinoma cells was performed (i.e., mixed-NETc). Phylogenetic analysis of mixed-NETc demonstrated that adenocarcinoma and neuroendocrine elements derive from a common precursor with mutations typical of adenocarcinomas. Over one-third (22/64) of NETc demonstrated a mutator phenotype of C > T at CpG consistent with deficiencies in MBD4, a member of the base excision repair (BER) pathway. Mutations in the PI3K/AMPK pathways were identified in 49/64 samples. We used two patient-derived-xenografts (PDX) (i.e., NET19 and NET21) to evaluate the activity of pan-HER (afatinib), PIK3CA (copanlisib), and ATR (elimusertib) inhibitors, alone and in combination. PDXs harboring alterations in the ERBB2/PI3K/AKT/mTOR/ATR pathway were sensitive to afatinib, copanlisib, and elimusertib (P < 0.001 vs. controls). However, combinations of copanlisib/afatinib and copanlisib/elimusertib were significantly more effective in controlling NETc tumor growth. These findings define the genetic landscape of NETc and suggest that a large subset of these highly lethal malignancies might benefit from existing targeted therapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:121 |
|---|---|
| Enthalten in: |
Proceedings of the National Academy of Sciences of the United States of America - 121(2024), 17 vom: 23. Apr., Seite e2321898121 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
41UD74L59M |
|---|
| Anmerkungen: |
Date Completed 18.04.2024 Date Revised 28.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1073/pnas.2321898121 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371150507 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371150507 | ||
| 003 | DE-627 | ||
| 005 | 20240428232040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240417s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1073/pnas.2321898121 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1391.xml |
| 035 | |a (DE-627)NLM371150507 | ||
| 035 | |a (NLM)38625939 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bellone, Stefania |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.04.2024 | ||
| 500 | |a Date Revised 28.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a High-grade neuroendocrine cervical cancers (NETc) are exceedingly rare, highly aggressive tumors. We analyzed 64 NETc tumor samples by whole-exome sequencing (WES). Human papillomavirus DNA was detected in 65.6% (42/64) of the tumors. Recurrent mutations were identified in PIK3CA, KMT2D/MLL2, K-RAS, ARID1A, NOTCH2, and RPL10. The top mutated genes included RB1, ARID1A, PTEN, KMT2D/MLL2, and WDFY3, a gene not yet implicated in NETc. Somatic CNV analysis identified two copy number gains (3q27.1 and 19q13.12) and five copy number losses (1p36.21/5q31.3/6p22.2/9q21.11/11p15.5). Also, gene fusions affecting the ACLY-CRHR1 and PVT1-MYC genes were identified in one of the eight samples subjected to RNA sequencing. To resolve evolutionary history, multiregion WES in NETc admixed with adenocarcinoma cells was performed (i.e., mixed-NETc). Phylogenetic analysis of mixed-NETc demonstrated that adenocarcinoma and neuroendocrine elements derive from a common precursor with mutations typical of adenocarcinomas. Over one-third (22/64) of NETc demonstrated a mutator phenotype of C > T at CpG consistent with deficiencies in MBD4, a member of the base excision repair (BER) pathway. Mutations in the PI3K/AMPK pathways were identified in 49/64 samples. We used two patient-derived-xenografts (PDX) (i.e., NET19 and NET21) to evaluate the activity of pan-HER (afatinib), PIK3CA (copanlisib), and ATR (elimusertib) inhibitors, alone and in combination. PDXs harboring alterations in the ERBB2/PI3K/AKT/mTOR/ATR pathway were sensitive to afatinib, copanlisib, and elimusertib (P < 0.001 vs. controls). However, combinations of copanlisib/afatinib and copanlisib/elimusertib were significantly more effective in controlling NETc tumor growth. These findings define the genetic landscape of NETc and suggest that a large subset of these highly lethal malignancies might benefit from existing targeted therapies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a genetic analysis | |
| 650 | 4 | |a mutations | |
| 650 | 4 | |a neuroendocrine | |
| 650 | 4 | |a oncogene | |
| 650 | 7 | |a Afatinib |2 NLM | |
| 650 | 7 | |a 41UD74L59M |2 NLM | |
| 650 | 7 | |a Phosphatidylinositol 3-Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.1.- |2 NLM | |
| 650 | 7 | |a Class I Phosphatidylinositol 3-Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.1.137 |2 NLM | |
| 700 | 1 | |a Jeong, Kyungjo |e verfasserin |4 aut | |
| 700 | 1 | |a Halle, Mari Kyllesø |e verfasserin |4 aut | |
| 700 | 1 | |a Krakstad, Camilla |e verfasserin |4 aut | |
| 700 | 1 | |a McNamara, Blair |e verfasserin |4 aut | |
| 700 | 1 | |a Greenman, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Mutlu, Levent |e verfasserin |4 aut | |
| 700 | 1 | |a Demirkiran, Cem |e verfasserin |4 aut | |
| 700 | 1 | |a Hartwich, Tobias Max Philipp |e verfasserin |4 aut | |
| 700 | 1 | |a Yang-Hartwich, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Zipponi, Margherita |e verfasserin |4 aut | |
| 700 | 1 | |a Buza, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Hui, Pei |e verfasserin |4 aut | |
| 700 | 1 | |a Raspagliesi, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Paolini, Biagio |e verfasserin |4 aut | |
| 700 | 1 | |a Milione, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Perrone, Emanuele |e verfasserin |4 aut | |
| 700 | 1 | |a Scambia, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Altwerger, Gary |e verfasserin |4 aut | |
| 700 | 1 | |a Ravaggi, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Bignotti, Eliana |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Gloria S |e verfasserin |4 aut | |
| 700 | 1 | |a Andikyan, Vaagn |e verfasserin |4 aut | |
| 700 | 1 | |a Clark, Mitchell |e verfasserin |4 aut | |
| 700 | 1 | |a Ratner, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Azodi, Masoud |e verfasserin |4 aut | |
| 700 | 1 | |a Schwartz, Peter E |e verfasserin |4 aut | |
| 700 | 1 | |a Quick, Charles M |e verfasserin |4 aut | |
| 700 | 1 | |a Angioli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Terranova, Corrado |e verfasserin |4 aut | |
| 700 | 1 | |a Zaidi, Samir |e verfasserin |4 aut | |
| 700 | 1 | |a Nandi, Shuvro |e verfasserin |4 aut | |
| 700 | 1 | |a Alexandrov, Ludmil B |e verfasserin |4 aut | |
| 700 | 1 | |a Siegel, Eric R |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Jungmin |e verfasserin |4 aut | |
| 700 | 1 | |a Schlessinger, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Santin, Alessandro D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Proceedings of the National Academy of Sciences of the United States of America |d 1915 |g 121(2024), 17 vom: 23. Apr., Seite e2321898121 |w (DE-627)NLM000008982 |x 1091-6490 |7 nnns |
| 773 | 1 | 8 | |g volume:121 |g year:2024 |g number:17 |g day:23 |g month:04 |g pages:e2321898121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1073/pnas.2321898121 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 121 |j 2024 |e 17 |b 23 |c 04 |h e2321898121 | ||